EUVIMEDEUVIMED entdecken
Crossref

Targeting BMP4 as a therapeutic strategy for neovascularization and fibrosis in age-related macular degeneration

Rong Luan, Shuzhan Xu, Manhong Xu, Manqiao Wang, Xinyuan Huang, Jie Wang, Qingbo Li, Yi Gong, Juping Liu, Yan Shao, Xiaorong Li

Experimental Eye Research · 2025

DOI: 10.1016/j.exer.2025.110348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Eye Research, 2025. Verfasst von Rong Luan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and S…. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein 4, Choroidal Neovascularization, Macular Degeneration, Carrier Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigates the role of bone morphogenetic protein-4 (BMP4) in age-related macular degeneration (AMD), with a focus on its effects on subretinal fibrosis and choroidal neovascularization (CNV). Using a mouse model of laser-induced CNV, we found that BMP4 expression was significantly elevated in CNV lesions. BMP4 was shown to promote fibroblast proliferation and their differentiation into myofibroblasts, as indicated by increased expression of α-smooth muscle actin (α-SMA). Additionally, BMP4 promoted the transition of endothelial progenitor cells (EPCs) into endothelial cells (ECs), a process that was modulated by mitochondrial function. Intravitreal administration of Noggin, a BMP4 inhibitor, significantly reduced CNV lesion volume and decreased the expression of CD31 and α-SMA, suggesting a decrease in neovascularization and fibrosis. These findings underscore BMP4's critical role in AMD pathogenesis by driving both angiogenesis and fibrosis. Targeting BMP4 with Noggin presents a promising therapeutic approach for AMD, addressing both neovascularization and fibrosis in a single intervention, and highlights BMP4 as a potential novel target for AMD therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Morphogenetic Protein 4Choroidal NeovascularizationMacular DegenerationCarrier ProteinsAnimalsMiceFibrosisMice, Inbred C57BLDisease Models, AnimalIntravitreal InjectionsCell ProliferationActinsCell DifferentiationEndothelial Progenitor CellsCells, CulturedMaleMyofibroblastsHumansNoggin Protein

Stichwörter der Autor:innen

Age-related macular degenerationBone morphogenetic protein 4Choroidal neovascularizationEndothelial progenitor cellSubretinal fibrosis

Substanzen

Bone Morphogenetic Protein 4Carrier ProteinsActinsNoggin ProteinBmp4 protein, mouse

Autor:innen und Institutionen

  • Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin,…

Zitieren

APA

Luan, R., Xu, S., Xu, M., Wang, M., Huang, X., Wang, J., Li, Q., Gong, Y., Liu, J., Shao, Y., & Li, X. (2025). Targeting BMP4 as a therapeutic strategy for neovascularization and fibrosis in age-related macular degeneration. Experimental Eye Research. https://doi.org/10.1016/j.exer.2025.110348

Vancouver

Luan R, Xu S, Xu M, Wang M, Huang X, Wang J, et al. Targeting BMP4 as a therapeutic strategy for neovascularization and fibrosis in age-related macular degeneration. Experimental Eye Research. 2025. doi:10.1016/j.exer.2025.110348

BibTeX
@article{Luan2025,
  author = {Luan, Rong and Xu, Shuzhan and Xu, Manhong and Wang, Manqiao and Huang, Xinyuan and Wang, Jie and Li, Qingbo and Gong, Yi and Liu, Juping and Shao, Yan and Li, Xiaorong},
  title = {Targeting BMP4 as a therapeutic strategy for neovascularization and fibrosis in age-related macular degeneration},
  journal = {Experimental Eye Research},
  year = {2025},
  doi = {10.1016/j.exer.2025.110348}
}
Kostenlos starten →